The share of newly prescribed buprenorphine prescriptions for opioid use disorder that were never dispensed almost doubled between 2020 and 2024, according to a CDC-led analysis published in… read more.
The over-the-counter approval of naloxone has not translated into equal access across the United States, according to a new cross-sectional study published in JAMA Network Open. Researchers conducting… read more.
Misuse of stimulant medications for attention deficit hyperactivity disorder (ADHD) has declined sharply. In 2023, approximately 3.7% of adults under age 30 misused these medications, down from 7.5%… read more.
More than 50 million Americans live with chronic pain; among them, approximately one in 10 take prescription opioids regularly. A new large-scale study led by Stanford Medicine suggests… read more.
Fear can be used strategically in public health messaging to encourage people to quit smoking and avoid tobacco use, according to a joint study by researchers from the… read more.
A recent study shows that the rapid increase of new nicotine products and the influence of the tobacco industry are perceived to significantly hinder the European countries’ ability… read more.
Although the United States requires a warning label on alcoholic beverages, alcohol-related deaths have risen steadily over the past two decades. However, new labels warning of specific disease… read more.
While cigarette exposures are decreasing for young children, electronic nicotine products are putting toddlers at new risk of inhalation, according to Rutgers Health researchers. Their study, published in JAMA Network… read more.
A new overview of the best available evidence worldwide for smoking cessation has found that nicotine‑containing e‑cigarettes appear to be more effective for smoking cessation than other interventions… read more.
In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder… read more.
Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including… read more.
A new randomised controlled trial has found promising evidence that the smoking cessation medication varenicline (Chantix/Champix) can help people with cannabis use disorder (CUD) to reduce cannabis use. … read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
